Endocrinol Metab > Volume 22(1); 2007 > Article
Journal of Korean Endocrine Society 2007;22(1):19-25.
DOI: https://doi.org/10.3803/jkes.2007.22.1.19    Published online February 1, 2007.
Lipid Profile Changes in Postmenopausal Korean Women Treated with Alendronate (10 mg) for 2 Years: Comparing with Control Group.
Il Woo Joo, Han Jin Oh
Department of Family Medicine, Cheil General Hospital, College of Medicine, Sungkyunkwan University, Korea.
Abstract
BACKGROUND
Bisphosphonate, which has been used for prevention and treatment of osteoporosis with the mechanism of inhibiting bone resorption, also has an association with the cholesterol synthethic process. This suggests that bisphosphonate might have benefit to improve the lipid profile in humans through a process that blocks the mevalonate-squalene pathway. However, few reports have revealed the relationship between the action of bisphosphonate and lipid metabolism in postmenopausal Korean women. We planned this study to determine the effect of alendronate (10 mg) on the serum lipid level in postmenopausal Korean women. Subjects and METHODS: We retrospectively evaluated the postmenopausal Korean women (aged over 50) who visited the Osteoporosis clinic in the Health Care Center in Seoul from March of 2003 to October of 2005. The changes of the serum lipid levels, including total cholesterol, triglyceride, and HDL cholesterol, after 2-years of alendronate 10 mg administration were evaluated and comparing to a control group. RESULTS: After 2-years alendronate (10 mg) administration, the total cholesterol was decreased by 11.8 +/- 3.7 mg/dL, and the HDL cholesterol was increased by 5.2 +/-1.4 mg/dL as compared to the baseline lipid level. Both of these results showed statistical significance. Changes of the triglyceride and fasting blood glucose also showed a decline by 15.4 +/-9.8 mg/dL and 6.0 +/-1.4 mg/dL, respectively, but this was not statistically significant. However, in the control group, the total cholesterol was increased by 9.4 +/-8.8 mg/dL, and the triglyceride was increased by 10.5 +/-7.2 mg/dL as compared to the baseline lipid level. Both of the results showed statistical significance. CONCLUSION: Alendronate might have a beneficial effect on lipid metabolism to decrease cholesterol and increase HDL. Taking into consideration about the postmenopausal increase in the cholesterol level, alendronate is recommended for the prevention of hyperlipidemia in postmenopausal women, in addition to preventing and treating osteoporosi
Key Words: Alendronate, Total cholesterol, HDL cholesterol, Triglyceride
TOOLS
METRICS Graph View
  • 0 Crossref
  •  0 Scopus
  • 567 View
  • 0 Download
Related articles


Editorial Office
101-2503, Lotte Castle President, 109 Mapo-daero, Mapo-gu, Seoul 04146, Korea​
Tel: +82-2-716-2428    Fax: +82-2-714-5103    E-mail: journal@endocrinology.or.kr                

Copyright © 2021 by Korean Endocrine Society.

Developed in M2PI

Close layer
prev next